Skip to content

Manuela Pellegrini

7 papers in the library · 381 citations · publishing 2005-2021

Papers

γ‐Hydroxybutyrate (GHB) in Humans

Annals of the New York Academy of Sciences August 1, 2006 Sergio Abanades, Magı́ Farré, Mireia Segura et al. 124 citations

Gamma-hydroxybutyrate (GHB) produces dose-related changes in subjective effects, showing a mixed stimulant-sedative pattern: initial feelings of euphoria, high, and liking, followed by mild-to-moderate sedation with impaired performance and balance. Single oral doses of 40, 50, 60, and 72 mg/kg were given to eight volunteers. Mean peak plasma concentrations ranged from 79.1 to 130.1 μg/L. Physiological and subjective effects were dose-dependent and related to plasma concentrations. Urinary excretion was mainly related to dose. The results suggest high abuse liability at the doses typically consumed.

Disposition of Gamma-Hydroxybutyric Acid in Conventional and Nonconventional Biologic Fluids After Single Drug Administration: Issues in Methodology and Drug Monitoring

Therapeutic Drug Monitoring February 1, 2007 Sergio Abanades, Magı́ Farré, Mireia Segura et al. 66 citations

After a single oral dose of 50 mg/kg sodium GHB, mean peak plasma concentrations reached 83.1 μg/mL at 30 minutes, then declined to 0.9 μg/mL at 6 hours. GHB appeared in oral fluid at levels one-third to one-fourth of plasma concentrations, with a half-life of about 1.2 hours compared to 0.7 hour in plasma. Less than 2% of the dose was excreted in urine, and sweat contained only low concentrations. Subjective effects followed a mixed sedative-stimulant pattern, peaking between 1 and 1.5 hours and lasting 2 hours, and were related to plasma concentrations. Oral fluid and sweat were not suitable for monitoring GHB consumption.

Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers.

Journal of pharmaceutical and biomedical analysis June 9, 2008 Simona Pichini, Mitona Pujadas, Emilia Marchei et al. 59 citations

A liquid chromatography-mass spectrometry (LC-MS) method was developed to measure ten designer drugs—including MDMA, several 2C-series phenethylamines, m-CPP, and tryptamines—in urine samples from 32 consumers. Solid-phase extraction at pH 6 was applied to both non-hydrolyzed and enzymatically hydrolyzed urine, with 3,4-methylendioxypropylamphetamine (MDPA) as an internal standard. Chromatographic separation used a C18 column with a gradient of ammonium bicarbonate and acetonitrile, and detection was performed in single ion monitoring mode with electrospray ionization. Limits of quantification ranged from 20 to 60 ng/mL, calibration curves were linear to 2000 ng/mL, and mean recoveries were 55.4–95.6%. Higher analyte concentrations in hydrolyzed samples indicated the presence of conjugated compounds.

Quantification of the plant-derived hallucinogen Salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking.

Rapid communications in mass spectrometry : RCM January 1, 2005 Simona Pichini, Sergio Abanades, Magí Farré et al. 58 citations

A gas chromatography–mass spectrometry method was developed and validated to measure Salvinorin A, the main active compound in the hallucinogenic plant Salvia divinorum, in plasma, urine, saliva, and sweat. The method uses 17-alpha-methyltestosterone as an internal standard and extracts the compound with a chloroform/isopropanol mixture. It was validated over a concentration range of 0.015–5 microg/mL for plasma, urine, and saliva, and 0.01–5 microg/patch for sweat, with mean recoveries of 77.1–92.7% and precision and accuracy better than 15%. When applied to two consumers after smoking 75 mg of plant leaves, Salvinorin A was detected in urine (2.4 and 10.9 ng/mL) and saliva (11.1 and 25.0 ng/mL), but not in sweat patches.

3,4-Methylenedioxymethamphetamine (MDMA) Intoxication in an Infant Chronically Exposed to Cocaine

Therapeutic Drug Monitoring July 22, 2005 Óscar García‐algar, Nuria L Pez, M. Á. Bonet et al. 39 citations

An infant admitted to a pediatric emergency department had accidentally ingested MDMA (ecstasy), detected through urine drug testing. The infant's hydrolyzed urine contained 11.7 mg/L of MDMA and 34.4 mg/L of its main metabolite HMMA. Symptoms including apparent febrile convulsions and cardiovascular side effects resolved within one day after treatment with benzodiazepines. Segmental hair analysis also revealed chronic exposure to cocaine. The mother consistently denied any drugs in the home, complicating diagnosis. Periodic clinical and laboratory follow-ups were recommended to monitor long-term effects of illicit drug exposure and to ensure the child's removal from dangerous environments.

Magic truffles or Philosopher's stones: a legal way to sell psilocybin?

Drug Testing and Analysis August 9, 2012 Manuela Pellegrini, Maria Concetta Rotolo, Emilia Marchei et al. 21 citations

A liquid chromatography–tandem mass spectrometry method was developed to rapidly measure psilocybin and psilocin in Psilocybe sclerotia, known as magic truffles. After a simple methanol extraction, the alkaloids were separated on a reversed-phase column and detected using electrospray ionization tandem mass spectrometry. The method was linear over the calibration range with correlation coefficients above 0.99, detection limits of 0.3 µg per 100 mg, and quantification limits of 1 µg per 100 mg. Only psilocybin was found in the examined sclerotia, with concentrations ranging from 59.3 to 167.8 µg per 100 mg of fresh material.

Acute Pharmacological Effects and Oral Fluid Biomarkers of the Synthetic Cannabinoid UR-144 and THC in Recreational Users

Biology March 24, 2021 Nunzia la Maida, Esther Papaseit, Lucía Martínez de Soto et al. 14 citations

Synthetic cannabinoid UR-144, monitored by the EU Early Warning System since 2012 for severe adverse effects, shows a similar cardiovascular profile to delta-9-tetrahydrocannabinol (THC) but with less intense subjective effects. In an observational study, 16 volunteers smoked joints containing either UR-144 (1 or 1.5 mg) or cannabis (10 or 20 mg THC). Both substances significantly increased systolic and diastolic blood pressure and heart rate. UR-144 produced lower scores on visual analog scales for stimulant-like and high effects compared to cannabis, and no hallucinogenic effects were observed. UR-144 was detectable in oral fluid, peaking at 20 minutes after smoking, offering a non-invasive biomarker of consumption. These preliminary findings require confirmation in larger samples.